Literature DB >> 6408187

Inhibitory activity of antibodies to human Ia-like determinants: comparison of intact and pepsin-digested antibodies.

A V Muchmore, M Megson, J M Decker, P Knudsen, D L Mann, S Broder.   

Abstract

Antibodies which react with products encoded by the human DR locus precipitate a biomolecular membrane glycoprotein complex with m.w. of 29,000 and 34,000 daltons. Such antibodies are directed against HLA-DR Ia-like antigens found on human B cells and human monocytes and have been shown previously to inhibit a variety of in vitro cellular and humoral immune reactions. We have compared the in vitro effects of such antibodies on two assays of human immunity: antigen-specific proliferation and polyclonal immunoglobulin production. Intact IgG fractions of a rabbit heteroantiserum (anti-P29,34), a human MT-2 locus alloantiserum (Ia 172), and a mouse monoclonal antibody (LB 3.1) markedly inhibited in vitro immune reactivities of human mononuclear cells. Interestingly, F(ab')2 preparations of these antibodies failed to inhibit these in vitro immune responses at the concentrations tested. These data suggest that under certain conditions, Fc domains play a critical role in the inhibitory activity of antibodies to Ia-like molecules.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6408187

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Immunoglobulin M antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon.

Authors:  D Y Leung; T Collins; L A Lapierre; R S Geha; J S Pober
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

2.  The role of MHC class II antigens in the flare up reaction of antigen-induced arthritis in mice.

Authors:  M F van den Broek; W B van den Berg; L B van de Putte
Journal:  Agents Actions       Date:  1986-12

3.  Monoclonal anti-Ia antibodies suppress the flare up reaction of antigen induced arthritis in mice.

Authors:  M F van den Broek; W B van den Berg; L B van de Putte
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

4.  Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts.

Authors:  T Collins; A J Korman; C T Wake; J M Boss; D J Kappes; W Fiers; K A Ault; M A Gimbrone; J L Strominger; J S Pober
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

5.  Human dermal fibroblasts present tetanus toxoid antigen to antigen-specific T cell clones.

Authors:  D T Umetsu; J S Pober; H H Jabara; W Fiers; E J Yunis; S J Burakoff; C S Reiss; R S Geha
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

6.  Allogeneic suppressive effects of pregnancy sera on monocytes of responding cells in human mixed lymphocyte reactions.

Authors:  M Nieda; T Juji; S Imao
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

7.  Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro.

Authors:  T Collins; L A Lapierre; W Fiers; J L Strominger; J S Pober
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

8.  Three distinct classes of regulatory cytokines control endothelial cell MHC antigen expression. Interactions with immune gamma interferon differentiate the effects of tumor necrosis factor and lymphotoxin from those of leukocyte alpha and fibroblast beta interferons.

Authors:  L A Lapierre; W Fiers; J S Pober
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

9.  Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome.

Authors:  D Y Leung; R S Geha; J W Newburger; J C Burns; W Fiers; L A Lapierre; J S Pober
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.